Acute Ischemic Stroke：市場分析及び予測（～2017）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 11
1.2 List of Figures 13
2 Introduction 14
2.1 Catalyst 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 19
3.1.3 Prognosis 22
3.1.4 Quality of Life 22
3.2 Symptoms 23
4 Epidemiology 24
4.1 Disease Background 24
4.2 Risk Factors and Comorbidities 26
4.2.1 Atrial fibrillation increases the risk of AIS by as much as 15 times 27
4.2.2 Hypertension elevates the risk of AIS by more than three times 28
4.2.3 The risk of AIS is almost identical in obese men and women 29
4.2.4 The risk of AIS increases with the duration of diabetes 29
4.2.5 Smoking increases the risk of AIS, which varies with the number of cigarettes smoked 30
4.2.6 Age is a strong predictor of AIS in both men and women 31
4.2.7 A family history of stroke, particularly a paternal history, is a strong predictor of stroke 32
4.2.8 Race/ethnicity is a strong predictor of AIS, and the risk varies with the different subtypes of AIS 33
4.3 Global and Historical Trends 34
4.3.1 US 36
4.3.2 France 40
4.3.3 Germany 41
4.3.4 Italy 43
4.3.5 Spain 45
4.3.6 UK 47
4.4 Forecast Methodology 49
4.4.1 Sources Used 52
4.4.2 Forecast Assumptions and Methods – Incident Cases of AIS 60
4.4.3 Forecast Assumptions and Methods – Prevalent Cases of AIS 64
4.4.4 Forecast Assumptions and Methods – AIS Recurrence Rate (%) 67
4.4.5 Sources Not Used 68
4.5 Epidemiological Forecast for AIS (2012-2022) 70
4.5.1 Incidence 70
4.5.2 Prevalence 78
4.5.3 AIS Recurrence Rate (%) 84
4.6 Discussion 85
4.6.1 Conclusions on Epidemiology Trends 85
4.6.2 Limitations of the Analysis 86
4.6.3 Strengths of the Analysis 87
5 Current Treatment Options 89
5.1 Overview 89
5.2 Product Profiles – Major Brands 94
5.2.1 Activase (alteplase) 94
5.2.2 Additional Therapies 99
6 Unmet Needs Assessment and Opportunity Analysis 102
6.1 Overview 102
6.2 Unmet Needs Analysis 103
6.2.1 Current Lack of Effective AIS Therapies 103
6.2.2 Public Awareness of Stroke Still Limited 104
6.2.3 An Extended Therapeutic Time Window is Needed 105
6.2.4 Safer Thrombolysis 107
6.2.5 Accessibility to Acute Stroke Care Should be on Par with Myocardial Infarction 107
6.3 Opportunity Analysis 109
6.3.1 Thrombolytics That Can Be Administered Beyond Nine Hours 109
6.3.2 Effective Neuroprotective Therapies 110
6.3.3 Novel Neurorestorative Therapies 110
6.3.4 Better Antithrombotic Agents for AIS 111
6.3.5 Targeting Inflammation in AIS 112
7 R&D Strategies 113
7.1 Overview 113
7.2 Clinical Trial Design 114
7.2.1 Future AIS Trial Design 116
8 Pipeline Assessment 119
8.1 Overview 119
8.2 Promising Drugs in Clinical Development 120
8.2.1 Desmoteplase 120
8.3 Innovative Early-Stage Approaches 126
9 Pipeline Valuation Analysis 128
9.1 Clinical Benchmark of Key Pipeline Drugs 128
9.2 Commercial Benchmark of Key Pipeline Drugs 129
9.3 Competitive Assessment 131
9.4 Top-Line Five-Year Forecast 132
9.4.1 US 133
9.4.2 5EU 135
10 Appendix 137
10.1 Bibliography 137
10.2 Abbreviations 151
10.3 Methodology 153
10.4 Forecasting Methodology 153
10.4.1 Diagnosed AIS Patients 153
10.4.2 Percent Drug-Treated Patients 153
10.4.3 Drugs Included in Each Therapeutic Class 154
10.4.4 Launch and Patent Expiry Dates 154
10.4.5 General Pricing Assumptions 155
10.4.6 Individual Drug Assumptions 156
10.4.7 Generic Erosion 157
10.4.8 Pricing of Pipeline Agents 157
10.5 Physicians and Specialists Included in this Study 158
10.6 About the Authors 159
10.6.1 Authors 159
10.6.2 Epidemiologist 160
10.6.3 Global Head of Healthcare 160
10.7 About GlobalData 161
10.8 Disclaimer 161